SEMALEAN: Semaglutide 12 Months — Fat -18.9%, Lean Stable, Handgrip +4.1 kg, Sarcopenic Obesity 49→33% in Women-Majority Cohort
BODY

SEMALEAN: Semaglutide 12 Months — Fat -18.9%, Lean Stable, Handgrip +4.1 kg, Sarcopenic Obesity 49→33% in Women-Majority Cohort

By Olivia · · Diabetes, Obesity and Metabolism
KO | EN

The SEMALEAN study, published in Diabetes, Obesity and Metabolism (October 2025), tracked 106 obese adults (68.9% women) on weekly semaglutide 2.4 mg for 12 months. Lean mass dropped 3 kg in the first seven months then stabilized, while handgrip strength rose 4.1 kg and sarcopenic obesity prevalence fell from 49% to 33%.

The Data

Alissou and colleagues led a prospective multicenter observational study. Mean BMI at enrollment was 46.3 kg/m² across 115 enrolled adults; 106 completed 12-month follow-up. Women comprised 68.9% of the analyzed cohort.

Semaglutide reached the target dose of 2.4 mg weekly by week 16. Assessments at baseline, 7 months, and 12 months used DEXA body composition, handgrip dynamometry, and EWGSOP2-based sarcopenic obesity criteria.

12-month results:

  • Weight -12.7% (-9.8% at 7 months)
  • Fat mass -18.9% (-14.3% at 7 months)
  • Visceral adipose tissue: sustained significant reduction
  • Lean mass: -3.0 kg at 7 months, stable thereafter
  • Handgrip strength: +3.7 kg at 7 months, +4.1 kg at 12 months
  • Sarcopenic obesity prevalence: 49% baseline → 33% at 12 months
  • ≥10% weight loss: 59% of patients; ≥15%: 26%

Women showed significantly greater changes in weight, fat mass, and lean mass than men. The investigators attributed differences to subcutaneous fat distribution and sex hormone effects on metabolism.

”Lean Mass Down, Function Up” — What That Means

GLP-1 receptor agonist therapy consistently produces lean mass loss. SEMALEAN clarified the temporal pattern: most loss occurs in the first seven months, then stabilizes. Lean mass includes muscle, water, connective tissue, and visceral organ mass, so a -3 kg figure cannot be equated with pure muscle loss.

The critical finding is that handgrip strength improved despite lean mass loss. Handgrip is a validated proxy for whole-body strength and a mortality predictor. A 4.1 kg gain in the context of 12.7% weight loss suggests functional recovery from reduced load combined with resolution of sarcopenic obesity, not simple muscle wasting.

Sarcopenic obesity — coexisting muscle deficit and excess adiposity — carries higher mortality than either condition alone. The absolute 16-percentage-point reduction (49% to 33%) is a 33% relative drop.

Why Women Respond More

Three mechanisms explain the sex difference:

  • Subcutaneous fat distribution: Women carry more gluteofemoral subcutaneous fat. Semaglutide preferentially mobilizes subcutaneous depots
  • Estrogen interaction: Higher estrogen levels enhance GLP-1 signaling sensitivity
  • Baseline composition: Women typically have lower lean mass percentage at the same BMI; absolute lean loss tracks proportionally, but functional handgrip recovery scales similarly or stronger

Perimenopausal hormonal changes alter GLP-1 response. Postmenopausal women face higher baseline muscle loss risk, making protein and resistance training more critical during therapy.

Clinical Application

  • Protein intake: 1.2–1.6 g/kg body weight daily (84–112 g for a 70 kg adult)
  • Resistance training: 2-3 sessions weekly, major muscle groups, 8-12 reps × 2-3 sets
  • Walking + daily activity: 150+ minutes weekly moderate intensity, supports lean preservation
  • Vitamin D: maintain 50 nmol/L+; supplement 800-2,000 IU daily if deficient
  • Calcium: 1,000-1,200 mg daily, food-first
  • Handgrip self-monitoring: women age 30s avg 25-30 kg, 40s 23-28 kg, 50s 20-25 kg. Track every 6 months
  • GI side effect management: nausea/constipation typically adapts in 1-3 months; reduce meal volume 30% and target 25 g fiber daily
  • Sarcopenic obesity screening: BMI 30+ with handgrip <16 kg (women) or SMI <5.5 indicates risk. Reassess at 12 months

The most important clinical takeaway from SEMALEAN: lean loss during GLP-1 therapy is not equivalent to muscle wasting. With protein, resistance training, and structured monitoring, sarcopenic obesity itself resolves.